CRL

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Wall Street analysts forecast CRL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRL is 192.73 USD with a low forecast of 165.00 USD and a high forecast of 225.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Charles River Laboratories International Inc revenue for the last quarter amounts to 1.00B USD, decreased -0.49 % YoY.

Charles River Laboratories International Inc. EPS for the last quarter amounts to 1.10 USD, decreased -17.29 % YoY.

Charles River Laboratories International Inc (CRL) has 18600 emplpoyees as of December 15 2025.

Today CRL has the market capitalization of 9.50B USD.